Get the Stockscreener App
4.21
1.41%
-0.06
After Hours:
4.21
Genfit Adr stock is traded at $4.21, with a volume of 5,732.
It is down -1.41% in the last 24 hours and down -23.59% over the past month.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
See More
Previous Close:
$4.27
Open:
$4.19
24h Volume:
5,732
Relative Volume:
0.41
Market Cap:
$210.11M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-5.7349
EPS:
-0.7341
Net Cash Flow:
-
1W Performance:
+0.24%
1M Performance:
-23.59%
6M Performance:
-18.88%
1Y Performance:
+32.14%
1-Day Range:
$4.175
$4.41
1-Week Range:
$4.175
$4.45
52-Week Range:
$3.1201
$6.4229
Genfit Adr Stock (GNFT) Company Profile
Compare GNFT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
4.21 | 210.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-23-20 | Upgrade | Stifel | Hold → Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Underperform |
| May-13-20 | Downgrade | Kepler | Buy → Reduce |
| May-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-12-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-29-19 | Reiterated | B. Riley FBR | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Apr-24-19 | Initiated | SVB Leerink | Outperform |
| Apr-22-19 | Initiated | Barclays | Overweight |
View All
Genfit Adr Stock (GNFT) Latest News
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading - MSN
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Genfit: New EASL-EASD-EASO guidelines include NIS2+TipRanks.com - TipRanks
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary ... - GlobeNewswire
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Home / Today's Market - InvestorPlace
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Is Genfit (GNFT) Stock a Solid Choice Right Now - Yahoo Movies UK
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
All You Need to Know About Flex (FLEX) Rating Upgrade to Strong Buy - Zacks Investment Research
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? - Yahoo New Zealand News
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
GENFIT: Ipsen and GENFIT enter into exclusive licensing - GlobeNewswire
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana - Yahoo Finance
Genfit (GNFT) Stock Price, News & AnalysisNASDAQ - MarketBeat
The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing - Yahoo Finance
Genfit Adr Stock (GNFT) Financials Data
There is no financial data for Genfit Adr (GNFT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):